167 related articles for article (PubMed ID: 25125499)
1. Ursodeoxycholyl lysophosphatidylethanolamide inhibits cholestasis- and hypoxia-induced apoptosis by upregulating antiapoptosis proteins.
Sellinger M; Xu W; Pathil A; Stremmel W; Chamulitrat W
Exp Biol Med (Maywood); 2015 Feb; 240(2):252-60. PubMed ID: 25125499
[TBL] [Abstract][Full Text] [Related]
2. Ursodeoxycholyl lysophosphatidylethanolamide protects against hepatic ischemia and reperfusion injury in mice.
Wang J; Deng X; Yi S; Pathil A; Zhang W; Setchell K; Stremmel W; Chamulitrat W
Shock; 2015 Apr; 43(4):379-86. PubMed ID: 25526375
[TBL] [Abstract][Full Text] [Related]
3. Bile salt-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent.
Chamulitrat W; Burhenne J; Rehlen T; Pathil A; Stremmel W
Hepatology; 2009 Jul; 50(1):143-54. PubMed ID: 19496180
[TBL] [Abstract][Full Text] [Related]
4. Ursodeoxycholyl lysophosphatidylethanolamide inhibits lipoapoptosis by shifting fatty acid pools toward monosaturated and polyunsaturated fatty acids in mouse hepatocytes.
Chamulitrat W; Liebisch G; Xu W; Gan-Schreier H; Pathil A; Schmitz G; Stremmel W
Mol Pharmacol; 2013 Nov; 84(5):696-709. PubMed ID: 23974795
[TBL] [Abstract][Full Text] [Related]
5. The synthetic bile acid-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide suppresses TNFα-induced liver injury.
Pathil A; Warth A; Chamulitrat W; Stremmel W
J Hepatol; 2011 Apr; 54(4):674-84. PubMed ID: 21146893
[TBL] [Abstract][Full Text] [Related]
6. Ursodeoxycholyl Lysophosphatidylethanolamide Protects Against CD95/FAS-Induced Fulminant Hepatitis.
Utaipan T; Otto AC; Gan-Schreier H; Chunglok W; Pathil A; Stremmel W; Chamulitrat W
Shock; 2017 Aug; 48(2):251-259. PubMed ID: 28060213
[TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholyl lysophosphatidylethanolamide protects against hepatic ischemia/reperfusion injury via phospholipid metabolism-mediated mitochondrial quality control.
Gu J; Zhang T; Guo J; Chen K; Wang G; Li H; Wang J
FASEB J; 2020 May; 34(5):6198-6214. PubMed ID: 32162746
[TBL] [Abstract][Full Text] [Related]
8. Mcl-1 suppresses abasic site repair following bile acid-induced hepatic cellular DNA damage.
Yu H; Zhang X; Liu R; Li H; Xiao X; Zhou Y; Wei C; Yang M; Liao M; Zhao J; Xia Z; Liao Q
Tumour Biol; 2017 Jul; 39(7):1010428317712102. PubMed ID: 28681695
[TBL] [Abstract][Full Text] [Related]
9. Augmenter of Liver Regeneration (ALR) regulates bile acid synthesis and attenuates bile acid-induced apoptosis via glycogen synthase kinase-3β (GSK-3β) inhibition.
Ibrahim S; Dayoub R; Saberi V; Buchner M; Melter M; Weiss TS
Exp Cell Res; 2020 Dec; 397(1):112343. PubMed ID: 33132196
[TBL] [Abstract][Full Text] [Related]
10. Anti-inflammatory properties of ursodeoxycholyl lysophosphatidylethanolamide in endotoxin-mediated inflammatory liver injury.
Ludwig JM; Zhang Y; Chamulitrat W; Stremmel W; Pathil A
PLoS One; 2018; 13(5):e0197836. PubMed ID: 29795632
[TBL] [Abstract][Full Text] [Related]
11. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease.
Pathil A; Mueller J; Warth A; Chamulitrat W; Stremmel W
Hepatology; 2012 May; 55(5):1369-78. PubMed ID: 22183915
[TBL] [Abstract][Full Text] [Related]
12. Comparison of different bile acid-phospholipid conjugates in acute hepatitis.
Pathil A; Warth A; Chamulitrat W; Stremmel W
Eur J Clin Invest; 2012 Feb; 42(2):130-8. PubMed ID: 21707612
[TBL] [Abstract][Full Text] [Related]
13. Ursodeoxycholyl lysophosphatidylethanolamide negatively regulates TLR-mediated lipopolysaccharide response in human THP-1-derived macrophages.
Horvatova A; Utaipan T; Otto AC; Zhang Y; Gan-Schreier H; Pavek P; Pathil A; Stremmel W; Chamulitrat W
Eur J Pharmacol; 2018 Apr; 825():63-74. PubMed ID: 29475064
[TBL] [Abstract][Full Text] [Related]
14. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
Pathil A; Liebisch G; Okun JG; Chamulitrat W; Schmitz G; Stremmel W
Eur J Clin Invest; 2015 Sep; 45(9):925-31. PubMed ID: 26108973
[TBL] [Abstract][Full Text] [Related]
15. Honokiol reduces oxidative stress, c-jun-NH2-terminal kinase phosphorylation and protects against glycochenodeoxycholic acid-induced apoptosis in primary cultured rat hepatocytes.
Park EJ; Kim SY; Zhao YZ; Sohn DH
Planta Med; 2006 Jun; 72(7):661-4. PubMed ID: 16732532
[TBL] [Abstract][Full Text] [Related]
16. Resistance of rat hepatocytes against bile acid-induced apoptosis in cholestatic liver injury is due to nuclear factor-kappa B activation.
Schoemaker MH; Gommans WM; Conde de la Rosa L; Homan M; Klok P; Trautwein C; van Goor H; Poelstra K; Haisma HJ; Jansen PL; Moshage H
J Hepatol; 2003 Aug; 39(2):153-61. PubMed ID: 12873810
[TBL] [Abstract][Full Text] [Related]
17. Ursodeoxycholyl lysophosphatidylethanolamide attenuates hepatofibrogenesis by impairment of TGF-β1/Smad2/3 signalling.
Pathil A; Mueller J; Ludwig JM; Wang J; Warth A; Chamulitrat W; Stremmel W
Br J Pharmacol; 2014 Nov; 171(22):5113-26. PubMed ID: 25041068
[TBL] [Abstract][Full Text] [Related]
18. Prevention of ursodeoxycholate hepatotoxicity in the rabbit by conjugation with N-methyl amino acids.
Schmassmann A; Hofmann AF; Angellotti MA; Ton-Nu HT; Schteingart CD; Clerici C; Rossi SS; Rothschild MA; Cohen BI; Stenger RJ
Hepatology; 1990 Jun; 11(6):989-96. PubMed ID: 2365296
[TBL] [Abstract][Full Text] [Related]
19. Silencing glycogen synthase kinase-3beta inhibits acetaminophen hepatotoxicity and attenuates JNK activation and loss of glutamate cysteine ligase and myeloid cell leukemia sequence 1.
Shinohara M; Ybanez MD; Win S; Than TA; Jain S; Gaarde WA; Han D; Kaplowitz N
J Biol Chem; 2010 Mar; 285(11):8244-55. PubMed ID: 20061376
[TBL] [Abstract][Full Text] [Related]
20. Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity.
Buryova H; Chalupsky K; Zbodakova O; Kanchev I; Jirouskova M; Gregor M; Sedlacek R
BMC Gastroenterol; 2013 Oct; 13():155. PubMed ID: 24172289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
